News Releases

Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH $85 Million Initial Public Offering Completed SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing

New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of Treatment SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced the pricing of its initial public offering

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced the appointments of Catherine Lee as senior vice

MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on discovering

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced that the U.S.

John McHutchison, AO, M.D., Appointed to Board of Directors Adding Significant Industry Experience and Drug Development Expertise SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class drugs to

- Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409 - 93% of patients showed liver fat reduction of at least 30% from baseline SAN DIEGO, Jan. 22, 2020 /PRNewswire/ -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the

SAN DIEGO, October 15, 2019  – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Hubert Chen, M.D., Chief Medical Officer, will present at the H.C.